NdPr China Domestic Price (VAT excluded)
Q4 FY17 36.5 USD/kg
vs
Q4 FY18 44.2 USD/kg
+7.7 USD/kg
= 21% appreciation NdPr values averaged over Q4 YoY.
Not so hard really.
With a 50% increase in sales volumes to Japan, combination increase in mkt share & underlying demand, it is a reasonable assumption Lynas would have realised greater than 21% appreciation in av NdPr sales values given RfS production 1447t, less 100t retained Q4 18, vs 1343t Q4 17.
The same Q comparison ASP:
Q4 FY17 A$15.9/kg
vs
Q4 FY18 A$21.3/kg
+A$5.4/kg
= 34% appreciation ASP averaged over Q4 YoY.
With Chinese exports basically static H1 YoY:
"China's cumulative exports of rare earths from January to June were 2,6297.4 tons, a decrease of 0.33%."
They realised a 26% increase in total sales value:
"From January to June, China exported 256.7 million US dollars, up 26% year-on-year."
http://newmat.chinaiol.com/xtcl/s/0713/87198776.html
Based on Lynas reported sales values YoY it should not be so difficult to understand price appreciation YoY had a far greater impact on Chinese export revenues jumping 26% H1 rather than any vague guess at a shift in sales mix.
- Forums
- ASX - By Stock
- LYC
- Malaysia and China
Malaysia and China, page-47
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LYC (ASX) to my watchlist
|
|||||
Last
$6.35 |
Change
-0.050(0.78%) |
Mkt cap ! $5.935B |
Open | High | Low | Value | Volume |
$6.46 | $6.47 | $6.34 | $19.83M | 3.109M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 11865 | $6.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.36 | 3637 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 6.350 |
4 | 5536 | 6.340 |
4 | 13908 | 6.330 |
6 | 42312 | 6.320 |
6 | 24381 | 6.310 |
Price($) | Vol. | No. |
---|---|---|
6.370 | 3462 | 2 |
6.380 | 18088 | 2 |
6.390 | 11392 | 2 |
6.400 | 16874 | 4 |
6.420 | 785 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online